Stay updated with the latest
news from Antag Therapeutics
Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors
Copenhagen, Denmark, 09 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces the election of Keith Leonard as Chairman of its Board of Directors. Keith is a...
Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist
AT7687 demonstrated a favorable safety and tolerability profile with no adverse GI tolerability signals identified Once-weekly dosing potential and demonstrated target engagement across the doses tested were confirmed Preclinical data from non-human primates showed...
Antag Therapeutics appoints obesity treatment pioneer Philip Just Larsen as Chief Executive Officer
Copenhagen, Denmark, 21 May 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces the appointment of Philip Just Larsen MD, PhD as Chief Executive Officer (CEO)....
Antag Therapeutics to present data on AT7687, its first-in-class GIPR antagonist peptide at the American Diabetes Association’s 2026 Scientific Sessions
Copenhagen, Denmark, 23 April 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces that it will deliver an oral presentation at the 2026 Scientific Sessions of the...
Antag Therapeutics demonstrates compelling potential of its novel GIPR antagonist for obesity, reporting excellent tolerability in Phase 1 and enhanced weight loss in amylin combination study
Copenhagen, Denmark, 8 January 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces topline data from two studies evaluating AT7687, its first-in-class GIPR...
Antag Therapeutics expands senior team to support clinical progress
Antag Therapeutics (“Antag” or “the Company”), a biopharmaceutical company pioneering novel treatments for obesity, today announces the appointment of three new hires to support the Company’s next phase of growth following the recent initiation of a Phase 1 trial of...
Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment
First subjects dosed in double-blind, placebo-controlled trial assessing AT-7687’s safety, tolerability, pharmacokinetics, and metabolic effects in healthy lean subjects and subjects living with obesity With strong genetic and...
Experienced Industry Leader Dr. Joerg Moeller Appointed as Chief Executive Officer of Antag Therapeutics
Former Head of Global R&D at Bayer AG and an exceptional leader with a wealth of experience across biopharma Pivotal time of transition as the company prepares to start clinical development of its first in-class lead candidate, AT-7687 in obesity AT-7687 offers a...
Antag Therapeutics Announces €80 Million Series A Financing
Round led by Versant Ventures with participation from founding investor Novo Holdings and new investors SR One, Dawn Biopharma and Pictet Entering Phase I testing for next-generation weight loss therapy by antagonizing GIPR Antag Therapeutics, a next-generation...
Antag Therapeutics Announces FDA Clearance ofInvestigational New Drug (IND) Application for LeadMolecule, AT-7687
Antag Therapeutics, a leading biopharmaceutical company focused on targeting the Glucose-Dependent Insulinotropic Polypeptide (GIP) receptor to pioneer novel treatments for obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted its...